Chronic Low Back Pain (CLBP)NCT03973788
Effects of Repetitive Transcranial Magnetic Stimulation on Pain Thresholds in Patients With Chronic Low Back Pain
A study testing repetitive transcranial magnetic stimulation (rTMS) in people with Chronic Low Back Pain (CLBP), run by Texas Woman's University at 1 site in United States.
Trial summary
Chronic low back pain (CLBP) is a common reason for which patients are treated with opioids. Because the misuse of prescription opioids has become a serious problem in the Uinted States, finding effective alternative non-pharmaceutical interventions for chronic pain management has become an urgent matter. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Chronic Low Back Pain (CLBP)
- What is being tested?
- repetitive transcranial magnetic stimulation (rTMS)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jul 2019to 13 Jan 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults 18 years of age or older
- Have LBP for more than 6 months
Who cannot join
- Previous low back surgery, systemic joint disease (e.g. rheumatoid arthritis),
- Fracture,
- Infection
- Tumor or cancer
- Cauda equina syndrome
- neurological disorders
Show all 18Show fewer
- Neuropathy
- Raynaud's Disease
- pregnancy,
- Inability to maintain the testing and treatment positions (i.e. sitting, supine hook-lying and prone-lying) for 15 minutes at a time.
- History of significant head trauma,
- Electrical, magnetic, or mechanical implantation (e.g. cardiac pacemakers or intracerebral vascular clip)
- Metal implantation in the head and neck areas
- History of seizures or unexplained loss of consciousness,
- Immediate family member with epilepsy
- Use of seizure threshold lowering medicine
- Current abuse of alcohol or drugs
- History of psychiatric illness requiring medication controls
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Immediate and Short-term Effects of Single-session Repetitive Transcranial Magnetic Stimulation on Pain Thresholds In Patients With Chronic Low Back Pain - A Pilot Study
Chronic low back pain (CLBP) is a common reason for which patients are treated with opioids. Because the misuse of prescription opioids has become a serious problem in the Uinted States, finding effective alternative non-pharmaceutical interventions for chronic pain management has become an urgent matter. A phenomenon termed central sensitization (i.e. mal-adaption of the brain) has been hypothesized to be an underlying mechanism for the development of chronic pain, leading to sensory hypersensitivity to extremal stimuli. Therefore, non-invasive brain stimulation, such as repetitive transcranial magnetic stimulation (rTMS) may be an effective intervention to regulate brain excitability, thus reducing chronic pain. However, research has shown inconclusive evidence regarding the rTMS effects on chronic pain reduction, partly due to the heterogeneity of participants in studies to date. Therefore, the primary purpose of this study is to investigate the immediate and short-term effects of rTMS on neurosensory changes (i.e., pain thresholds) in patients with CLBP. The secondary purpuse of the study is to explore the relationship between changes of cortical excitability (TMS parameters) and changes of pain thresholds after the rTMS intervention in patients with CLBP.
Read the detailed description
Research Design
A pre- and post-test research design will be used to examine the immediate and one-week carry-over effects of a single-session of rTMS intervention on individuals with CLBP. The primary outcome measures, including PPT, cold pain threshold (CPT), heat pain threshold (HPT), and heat-generated temporal summation (TS), will be collected three times: before the rTMS intervention, immediately after the intervention, and one week after the intervention.
Participants
Eligible participants are adults 18 years of age or older and who have had LBP for more than 6 months. According to the Centers for Disease Control and Prevention, chronic pain is defined as pain lasts more than 3 months or past the time of normal tissue healing. In order to ensure the development of central sensitization in the investigator's participants, only individuals with LBP for more than 6 months will be enrolled in this study.
Participants will be excluded from the study if they have previous low back surgery, systemic joint disease (e.g. rheumatoid arthritis), evidence of red flags (e.g. fracture, infection, tumor, cauda equina syndrome), cancer, neurological disorders, neuropathy, Raynaud's Disease or pregnancy, and inability to maintain the testing and treatment positions (i.e. sitting, supine hook-lying and prone-lying) for 15 minutes at a time. Additional exclusion criteria for the rTMS intervention include: 1) history of significant head trauma, 2) electrical, magnetic, or mechanical implantation (e.g. cardiac pacemakers or intracerebral vascular clip), 3) metal implantation in the head and neck areas, 4) history of seizures or unexplained loss of consciousness, 5) immediate family member with epilepsy, 6) use of seizure threshold lowering medicine, 7) current abuse of alcohol or drugs, and 8) history of psychiatric illness requiring medication controls.
Procedure
After the participant is enrolled the study, the participant will be asked to complete an intake form, collecting their demographic data (age, gender, height, weight, occupation, hand dominance), past medical history, and questions related to their low back pain (onset, injury mechanism if any, location, duration, type, and nature). In addition, 4 self-reported questionnaires will be collected from all of the participants before the rTMS treatment, including pain intensity determined using the NPRS, disability determined using the Modified Oswestry Low Back Pain Disability Questionnaire quality of life determined by the Patient-Reported Outcomes Measurement Information System® - short form (PROMIS-29), and severity of central sensitization determined by the Central Sensitization Inventory (CSI ). These questionnaires are commonly used in research studies of chronic pain or CLBP.
- Pain Threshold Tests: All participants will undergo a battery of tests to determine their sensory thresholds, including pressure, cold and heat pain thresholds and heat-generated temporal summation (TS). The pain thresholds and TS will be measured from three sites: the most painful point of low back, as well as the web space (WS) and the tibialis anterior (TA) of the painful side. Those who report no pain difference between the right and left low back, pain thresholds will be measured from the right side. The TA testing site will be in the muscle belly of the TA, approximately 2.5 cm lateral and 5 cm inferior to the tibial tubercle. The WS and TA sites were chosen because they are the most commonly selected sites in research studies for chronic pain. In addition, the first interosseous index (FDI) is located in the WS, where is the target site for the TMS assessment and intervention. Pressure pain threshold (PPT) testing: A hand-held computerized pressure algometer (Medoc ltd., Ramat Yishai, Israel) will be used to measure the PPTs. The algometer consists of a 1-sqaure centermeter round tip which will be pressed vertically on the target location of the muscle. To provoke the patient's pain or discomfort, pressure will be increased at a rate of 40 kPa/sec until the participant feels pain as indicated by pressing a patient safety unit. The limit of pressure threshold will be set at 800 kPa, meaning that a pressure exceeding 800 kPa will be cut off to minimize tissue damage. If the participant does not push the button at 800 kPa, a value of 800 is used as the threshold value. Three trials of PPT testing will be administered to each testing site, and the average of the three trials will be used for data analysis. Cold and heat pain threshold testing: A Medoc TSA II Neurosensory Analyzer (Medoc ltd., Ramat Yishai, Israel) will be used to measure heat and cold pain thresholds. All thermal pain threshold tests will be obtained with ramped stimuli (0°5 C/s) which can be terminated when the participant presses a safety button. Cut-off temperatures will be set 0 and 52°C, and the baseline temperature will be set at 32°C (i.e., average skin temperature). The contact area of the thermode is 23mmx30mm. All thermal pain threshold tests will be demonstrated first at an area somewhere other than the three testing sites. Three trials of thermal pain threshold tests will be administered per testing site and the average of the three trials will be used for statistical analysis. Heat-generated temporal summation (TS) testing: The instrument used for measuring cold and heat pain thresholds will be used for the heat-generated TS test. During TS testing, 10 consecutive heat pulses of 0.5 sec duration will be delivered at an inter-stimulus interval of 2.5 sec. The temperature of the heat stimuli will increase from 40°C as a baseline temperature and inter-stimulus temperature, to 48°C at a rate of 8°C/sec. Participants will be asked to rate their pain intensity of each heat pulse on the NPRS of 0-100 (0 being no pain, 100 being unbearable pain). The TS score will be calculated by averaging the pain rating for the 10th stimulus and the 5th stimulus minus the 1st pain rating, with higher score indicating greater hypersensitivity of pain.
- Cortical Excitability Assessment A series of single pulse generated from a TMS machine (Rapid2, Magstim Co., UK) will be used to determine corticospinal excitability. Because the rTMS intervention will target the M1 area, specifically in the area corresponding to the FDI muscle, motor evoked potentials (MEPs), namely electromyographic (EMG) activity, will be recorded from the FDI muscle to determine the "hot spot" for the rTMS intervention. A hot spot is defined as the site at which the largest MEP amplitude is obtained at the lowest TMS stimulation intensity. First, a pair of surface EMG electrodes will be placed on the FDI muscle when the participant is seated on a reclining chair and wearing a pair of earplugs to reduce their awareness of noise from the rTMS equipment. Similar to the pain threshold testing on the low back, EMG activity will be measured from FDI muscle on the same side of the patient as the LBP. For those who report no difference in LBP between sides, EMG data will be recorded from the FDI of the right hand. The Mega 600 EMG machine (Mega Electronics Ltd., Finland) will be used to collect EMG data at a sampling rate of 2,000Hz and bandpass-filtered at 15-500Hz. During the cortical excitability assessment, each participant will wear a Lycra swimming cap with a pre-marked grid. The intensity of TMS will begin at 40% of maximum stimulator output and then will be increased gradually to yield a MEP from the FDI until a 'hot spot' is observed. Next, the resting motor threshold (RMT) will be defined. RMT is the stimulation intensity which yields a peak-to-peak amplitude of MEP larger than 50 μV in 5 out of 10 consecutive trials. Once the RMT is determined, the stimulation intensity will be set at 120% of RMT and 10 stimulations will be delivered to the hot-spot. The 10 supra-threshold MEP amplitudes recorded from the FDI will be averaged and the average will be used for the representation of corticospinal excitability.
- rTMS Intervention
After the corticospinal excitability assessment, participants will receive 10Hz rTMS delivered to the hot-spot contralateral to the painful side in the form of twenty 10-second pulse trains (a total of 2,000 pulses) with a 50-second inter-train interval. The rTMS will be delivered via an air-filled coil (see figure to the right). The stimulation intensity will be set at 90% of RMT. After the rTMS intervention, the participant's corticospinal excitability will be re-assessed using the single-pulse TMS method as described earlier.
- Conditions
- Chronic Low Back Pain (CLBP)
- Being tested
- repetitive transcranial magnetic stimulation (rTMS)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
repetitive transcranial magnetic stimulation (rTMS)Procedure or surgery
A single section of rTMS (2,000 pulses)
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | repetitive transcranial magnetic stimulation Receives: Procedure: repetitive transcranial magnetic stimulation (rTMS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain thresholds
pressure pain thresholds, cold pain thresholds, and heat pain thresholds, and heat-generated temporal summation using a A Medoc TSA II Neurosensory Analyzer (Medoc ltd., Ramat Yishai, Israel).
Measured: before intervention, immediate after intervention, and one week after intervention
Secondary outcomes (1)
Cortical Excitability
10 supra-threshold motor evoked potentials (MEP) amplitudes recorded from the first interosseous index (FDI) muscle using a transcranial magnetic stimulation machine (Rapid2, Magstim Co., UK)
Measured: before intervention and immediate after intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2019
- Study start1 Jul 2019
- Primary completion31 Jan 2021
- Study completion13 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Low Back Pain (CLBP)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Pre and post test
- Masking
- None (open label)
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Texas Woman's University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sharon Wang-Price, Texas Woman's University
- Investigators
- Sharon Wang-Price, Principal investigator, Texas Woman's University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03973788
- Sponsor's protocol ID
- 20394
- Status last verified
- Jan 2026
- First submitted
- 30 May 2019
- Last updated
- 9 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The data that support the findings of this study are available on request from the corresponding author, Sharon Wang-Price. The data are not publicly available due to their containing information that could compromise the privacy of research participants.
Study at a glance
From the registry record, last updated by the sponsor on 9 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Immediate and Short-term Effects of Single-session Repetitive Transcranial Magnetic Stimulation on Pain Thresholds In Patients With Chronic Low Back Pain - A Pilot Study
- ClinicalTrials.gov ID
- NCT03973788
- Acronym / sponsor ID
- 20394
- Conditions
- Chronic Low Back Pain (CLBP)
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Texas Woman's UniversityUniversity, hospital or other
- Study start
- 1 Jul 2019 (actual)
- Primary completion
- 31 Jan 2021 (actual)
- Study completion
- 13 Jan 2022 (actual)
- First posted
- 4 Jun 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic low back pain (CLBP) is a common reason for which patients are treated with opioids. Because the misuse of prescription opioids has become a serious problem in the Uinted States, finding effective alternative non-pharmaceutical interventions for chronic pain management has become an urgent matter. A phenomenon termed central sensitization (i.e. mal-adaption of the brain) has been hypothesized to be an underlying mechanism for the development of chronic pain, leading to sensory hypersensitivity to extremal stimuli. Therefore, non-invasive brain stimulation, such as repetitive transcranial magnetic stimulation (rTMS) may be an effective intervention to regulate brain excitability, thus reducing chronic pain. However, research has shown inconclusive evidence regarding the rTMS effects on chronic pain reduction, partly due to the heterogeneity of participants in studies to date. Therefore, the primary purpose of this study is to investigate the immediate and short-term effects of rTMS on neurosensory changes (i.e., pain thresholds) in patients with CLBP. The secondary purpuse of the study is to explore the relationship between changes of cortical excitability (TMS parameters) and changes of pain thresholds after the rTMS intervention in patients with CLBP.
Detailed description
Research Design
A pre- and post-test research design will be used to examine the immediate and one-week carry-over effects of a single-session of rTMS intervention on individuals with CLBP. The primary outcome measures, including PPT, cold pain threshold (CPT), heat pain threshold (HPT), and heat-generated temporal summation (TS), will be collected three times: before the rTMS intervention, immediately after the intervention, and one week after the intervention.
Participants
Eligible participants are adults 18 years of age or older and who have had LBP for more than 6 months. According to the Centers for Disease Control and Prevention, chronic pain is defined as pain lasts more than 3 months or past the time of normal tissue healing. In order to ensure the development of central sensitization in the investigator's participants, only individuals with LBP for more than 6 months will be enrolled in this study.
Participants will be excluded from the study if they have previous low back surgery, systemic joint disease (e.g. rheumatoid arthritis), evidence of red flags (e.g. fracture, infection, tumor, cauda equina syndrome), cancer, neurological disorders, neuropathy, Raynaud's Disease or pregnancy, and inability to maintain the testing and treatment positions (i.e. sitting, supine hook-lying and prone-lying) for 15 minutes at a time. Additional exclusion criteria for the rTMS intervention include: 1) history of significant head trauma, 2) electrical, magnetic, or mechanical implantation (e.g. cardiac pacemakers or intracerebral vascular clip), 3) metal implantation in the head and neck areas, 4) history of seizures or unexplained loss of consciousness, 5) immediate family member with epilepsy, 6) use of seizure threshold lowering medicine, 7) current abuse of alcohol or drugs, and 8) history of psychiatric illness requiring medication controls.
Procedure
After the participant is enrolled the study, the participant will be asked to complete an intake form, collecting their demographic data (age, gender, height, weight, occupation, hand dominance), past medical history, and questions related to their low back pain (onset, injury mechanism if any, location, duration, type, and nature). In addition, 4 self-reported questionnaires will be collected from all of the participants before the rTMS treatment, including pain intensity determined using the NPRS, disability determined using the Modified Oswestry Low Back Pain Disability Questionnaire quality of life determined by the Patient-Reported Outcomes Measurement Information System® - short form (PROMIS-29), and severity of central sensitization determined by the Central Sensitization Inventory (CSI ). These questionnaires are commonly used in research studies of chronic pain or CLBP.
- Pain Threshold Tests: All participants will undergo a battery of tests to determine their sensory thresholds, including pressure, cold and heat pain thresholds and heat-generated temporal summation (TS). The pain thresholds and TS will be measured from three sites: the most painful point of low back, as well as the web space (WS) and the tibialis anterior (TA) of the painful side. Those who report no pain difference between the right and left low back, pain thresholds will be measured from the right side. The TA testing site will be in the muscle belly of the TA, approximately 2.5 cm lateral and 5 cm inferior to the tibial tubercle. The WS and TA sites were chosen because they are the most commonly selected sites in research studies for chronic pain. In addition, the first interosseous index (FDI) is located in the WS, where is the target site for the TMS assessment and intervention. Pressure pain threshold (PPT) testing: A hand-held computerized pressure algometer (Medoc ltd., Ramat Yishai, Israel) will be used to measure the PPTs. The algometer consists of a 1-sqaure centermeter round tip which will be pressed vertically on the target location of the muscle. To provoke the patient's pain or discomfort, pressure will be increased at a rate of 40 kPa/sec until the participant feels pain as indicated by pressing a patient safety unit. The limit of pressure threshold will be set at 800 kPa, meaning that a pressure exceeding 800 kPa will be cut off to minimize tissue damage. If the participant does not push the button at 800 kPa, a value of 800 is used as the threshold value. Three trials of PPT testing will be administered to each testing site, and the average of the three trials will be used for data analysis. Cold and heat pain threshold testing: A Medoc TSA II Neurosensory Analyzer (Medoc ltd., Ramat Yishai, Israel) will be used to measure heat and cold pain thresholds. All thermal pain threshold tests will be obtained with ramped stimuli (0°5 C/s) which can be terminated when the participant presses a safety button. Cut-off temperatures will be set 0 and 52°C, and the baseline temperature will be set at 32°C (i.e., average skin temperature). The contact area of the thermode is 23mmx30mm. All thermal pain threshold tests will be demonstrated first at an area somewhere other than the three testing sites. Three trials of thermal pain threshold tests will be administered per testing site and the average of the three trials will be used for statistical analysis. Heat-generated temporal summation (TS) testing: The instrument used for measuring cold and heat pain thresholds will be used for the heat-generated TS test. During TS testing, 10 consecutive heat pulses of 0.5 sec duration will be delivered at an inter-stimulus interval of 2.5 sec. The temperature of the heat stimuli will increase from 40°C as a baseline temperature and inter-stimulus temperature, to 48°C at a rate of 8°C/sec. Participants will be asked to rate their pain intensity of each heat pulse on the NPRS of 0-100 (0 being no pain, 100 being unbearable pain). The TS score will be calculated by averaging the pain rating for the 10th stimulus and the 5th stimulus minus the 1st pain rating, with higher score indicating greater hypersensitivity of pain.
- Cortical Excitability Assessment A series of single pulse generated from a TMS machine (Rapid2, Magstim Co., UK) will be used to determine corticospinal excitability. Because the rTMS intervention will target the M1 area, specifically in the area corresponding to the FDI muscle, motor evoked potentials (MEPs), namely electromyographic (EMG) activity, will be recorded from the FDI muscle to determine the "hot spot" for the rTMS intervention. A hot spot is defined as the site at which the largest MEP amplitude is obtained at the lowest TMS stimulation intensity. First, a pair of surface EMG electrodes will be placed on the FDI muscle when the participant is seated on a reclining chair and wearing a pair of earplugs to reduce their awareness of noise from the rTMS equipment. Similar to the pain threshold testing on the low back, EMG activity will be measured from FDI muscle on the same side of the patient as the LBP. For those who report no difference in LBP between sides, EMG data will be recorded from the FDI of the right hand. The Mega 600 EMG machine (Mega Electronics Ltd., Finland) will be used to collect EMG data at a sampling rate of 2,000Hz and bandpass-filtered at 15-500Hz. During the cortical excitability assessment, each participant will wear a Lycra swimming cap with a pre-marked grid. The intensity of TMS will begin at 40% of maximum stimulator output and then will be increased gradually to yield a MEP from the FDI until a 'hot spot' is observed. Next, the resting motor threshold (RMT) will be defined. RMT is the stimulation intensity which yields a peak-to-peak amplitude of MEP larger than 50 μV in 5 out of 10 consecutive trials. Once the RMT is determined, the stimulation intensity will be set at 120% of RMT and 10 stimulations will be delivered to the hot-spot. The 10 supra-threshold MEP amplitudes recorded from the FDI will be averaged and the average will be used for the representation of corticospinal excitability.
- rTMS Intervention
After the corticospinal excitability assessment, participants will receive 10Hz rTMS delivered to the hot-spot contralateral to the painful side in the form of twenty 10-second pulse trains (a total of 2,000 pulses) with a 50-second inter-train interval. The rTMS will be delivered via an air-filled coil (see figure to the right). The stimulation intensity will be set at 90% of RMT. After the rTMS intervention, the participant's corticospinal excitability will be re-assessed using the single-pulse TMS method as described earlier.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Pre and post test
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Procedure: repetitive transcranial magnetic stimulation (rTMS)repetitive transcranial magnetic stimulation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Adults 18 years of age or older
- Have LBP for more than 6 months
Key exclusion criteria (18 listed)
- Previous low back surgery, systemic joint disease (e.g. rheumatoid arthritis),
- Fracture,
- Infection
- Tumor or cancer
- Cauda equina syndrome
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| repetitive transcranial magnetic stimulation (rTMS)A single section of rTMS (2,000 pulses) | Procedure or surgery | Intervention |
Primary outcome
Pain thresholds
Time frame: before intervention, immediate after intervention, and one week after intervention
pressure pain thresholds, cold pain thresholds, and heat pain thresholds, and heat-generated temporal summation using a A Medoc TSA II Neurosensory Analyzer (Medoc ltd., Ramat Yishai, Israel).
1 secondary outcome
Cortical Excitability
Time frame: before intervention and immediate after intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jan 2026.
- Individual participant dataSharing planned: No. The data that support the findings of this study are available on request from the corresponding author, Sharon Wang-Price. The data are not publicly available due to their containing information that could compromise the privacy of research participants.
Related trials for Chronic Low Back Pain (CLBP)
Not yet recruiting
Comparing Non-Medicine Strategies for Improving Low Back Pain
Chronic Low-back Pain (cLBP), High-Impact Chronic Pain (HICP)
Not yet recruiting
Spinery Basivertebral Nerve Ablation for Vertebrogenic Chronic Low Back Pain
Low Back Pain, Chronic Low Back Pain (CLBP)
Recruiting
SENECA - Smart Therapies for Chronic Pain
Chronic Low Back Pain (CLBP)
Not yet recruiting
Comparison of Two Patient Education Methods in Women With Chronic Low Back Pain: Online Pain Education vs. AI-Driven Patient Education on Pain Beliefs, Catastrophizing, and Self-Efficacy
Chronic Low Back Pain (CLBP)
Not yet recruiting
Effects of Myofascial Techniques on Chronic Low Back Pain
Chronic Low-back Pain (cLBP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sharon Wang-Price principal investigator
Texas Woman's University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing repetitive transcranial magnetic stimulation (rTMS) in people with Chronic Low Back Pain (CLBP), run by Texas Woman's University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain thresholds (time frame: before intervention, immediate after intervention, and one week after intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2026.